159 related articles for article (PubMed ID: 15951531)
1. Reinforcing the mucus: a new therapeutic approach for ulcerative colitis?
Gibson PR; Muir JG
Gut; 2005 Jul; 54(7):900-3. PubMed ID: 15951531
[TBL] [Abstract][Full Text] [Related]
2. Lecithin as a therapeutic agent in ulcerative colitis.
Stremmel W; Gauss A
Dig Dis; 2013; 31(3-4):388-90. PubMed ID: 24246994
[TBL] [Abstract][Full Text] [Related]
3. There is a 'uc' in mucus, but is there mucus in UC?
McGuckin MA; Hasnain SZ
Gut; 2014 Feb; 63(2):216-7. PubMed ID: 23595349
[No Abstract] [Full Text] [Related]
4. [Mucosal protection by phosphatidylcholine as new therapeutic concept in ulcerative colitis].
Stremmel W
Z Gastroenterol; 2013 Apr; 51(4):384-9. PubMed ID: 23585269
[TBL] [Abstract][Full Text] [Related]
5. Colonic mucus, smoking and ulcerative colitis.
Pullan RD
Ann R Coll Surg Engl; 1996 Mar; 78(2):85-91. PubMed ID: 8678464
[TBL] [Abstract][Full Text] [Related]
6. Delayed release phosphatidylcholine as new therapeutic drug for ulcerative colitis--a review of three clinical trials.
Stremmel W; Hanemann A; Braun A; Stoffels S; Karner M; Fazeli S; Ehehalt R
Expert Opin Investig Drugs; 2010 Dec; 19(12):1623-30. PubMed ID: 21105858
[TBL] [Abstract][Full Text] [Related]
7. Phosphatidylcholine and lysophosphatidylcholine in intestinal mucus of ulcerative colitis patients. A quantitative approach by nanoElectrospray-tandem mass spectrometry.
Ehehalt R; Wagenblast J; Erben G; Lehmann WD; Hinz U; Merle U; Stremmel W
Scand J Gastroenterol; 2004 Aug; 39(8):737-42. PubMed ID: 15513358
[TBL] [Abstract][Full Text] [Related]
8. The in vivo and in vitro study of polysaccharides from a two-herb formula on ulcerative colitis and potential mechanism of action.
Zhao L; Wu H; Zhao A; Lu H; Sun W; Ma C; Yang Y; Xin X; Zou H; Qiu M; Jia W
J Ethnopharmacol; 2014 Apr; 153(1):151-9. PubMed ID: 24548752
[TBL] [Abstract][Full Text] [Related]
9. Beneficial role of the probiotic mixture Ultrabiotique on maintaining the integrity of intestinal mucosal barrier in DSS-induced experimental colitis.
Toumi R; Abdelouhab K; Rafa H; Soufli I; Raissi-Kerboua D; Djeraba Z; Touil-Boukoffa C
Immunopharmacol Immunotoxicol; 2013 Jun; 35(3):403-9. PubMed ID: 23638770
[TBL] [Abstract][Full Text] [Related]
10. Immunosuppressive and biologic therapy for ulcerative colitis.
Ardizzone S; Cassinotti A; de Franchis R
Expert Opin Emerg Drugs; 2012 Dec; 17(4):449-67. PubMed ID: 23163556
[TBL] [Abstract][Full Text] [Related]
11. The condition of the biliary tract and cholesecretion in cases of ulcerative colitis.
Abasov IT; Isaev EG; Iof IM
Hepatogastroenterology; 1985 Jun; 32(3):138-40. PubMed ID: 4018708
[TBL] [Abstract][Full Text] [Related]
12. Comparative study of the intestinal mucus barrier in normal and inflamed colon.
Swidsinski A; Loening-Baucke V; Theissig F; Engelhardt H; Bengmark S; Koch S; Lochs H; Dörffel Y
Gut; 2007 Mar; 56(3):343-50. PubMed ID: 16908512
[TBL] [Abstract][Full Text] [Related]
13. Proteins and peptides: The need to improve them as promising therapeutics for ulcerative colitis.
Sahu KK; Minz S; Kaurav M; Pandey RS
Artif Cells Nanomed Biotechnol; 2016; 44(2):642-53. PubMed ID: 25379956
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Potential to Modify the Mucus Barrier in Inflammatory Bowel Disease.
Sun J; Shen X; Li Y; Guo Z; Zhu W; Zuo L; Zhao J; Gu L; Gong J; Li J
Nutrients; 2016 Jan; 8(1):. PubMed ID: 26784223
[TBL] [Abstract][Full Text] [Related]
15. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis.
Sugimoto K; Ogawa A; Mizoguchi E; Shimomura Y; Andoh A; Bhan AK; Blumberg RS; Xavier RJ; Mizoguchi A
J Clin Invest; 2008 Feb; 118(2):534-44. PubMed ID: 18172556
[TBL] [Abstract][Full Text] [Related]
16. [Adalimumab for the treatment of ulcerative colitis--a consensus report by the working group inflammatory bowel diseases of the Austrian Society of Gastroenterology and Hepatology].
Novacek G; Dejaco C; Knoflach P; Moschen A; Petritsch W; Vogelsang H; Reinisch W
Z Gastroenterol; 2014 Feb; 52(2):204-11. PubMed ID: 24488763
[TBL] [Abstract][Full Text] [Related]
17. Ulcerative colitis activity index: a useful prognostic factor for predicting ulcerative colitis outcome.
Gürel S; Kiyici M
J Int Med Res; 2005; 33(1):103-10. PubMed ID: 15651722
[TBL] [Abstract][Full Text] [Related]
18. Elevated markers of thrombin generation and fibrinolysis in patients with active and quiescent ulcerative colitis.
Zezos P; Papaioannou G; Nikolaidis N; Patsiaoura K; Vassiliadis T; Mpoumponaris A; Giouleme O; Evgenidis N
Med Sci Monit; 2009 Nov; 15(11):CR563-72. PubMed ID: 19865055
[TBL] [Abstract][Full Text] [Related]
19. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease.
Sartor RB
Gastroenterol Clin North Am; 1995 Sep; 24(3):475-507. PubMed ID: 8809232
[TBL] [Abstract][Full Text] [Related]
20. Smoking and colonic mucus in ulcerative colitis.
Cope GF; Heatley RV; Kelleher JK
Br Med J (Clin Res Ed); 1986 Aug; 293(6545):481. PubMed ID: 3091168
[No Abstract] [Full Text] [Related]
[Next] [New Search]
